Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen

DB16713ApprovedInvestigationalVaccines

Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 8 individually conjugated to... The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.

First approval: United States, 2021
Brand names: Capvaxive
Prevnar 20

Resolves to

Compound

UNIIADR2S9OIF2

Clinical / RWD

RxNorm2566295

What you can answer from here — as of August 01, 2026

25Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

3Marketed productsAcross 1 country and 3 labellers

Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 8 capsular polysaccharide diphtheria CRM197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account